7-methyl-1,2-dihydroquinoline | 860199-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-methyl-1,2-dihydroquinoline
• 英文别名: 7-Methyl-1,2-dihydro-chinolin
• CAS: 860199-33-3
• 化学式: C₁₀H₁₁N
• mdl: MFCD19221155
• 分子量: 145.204
• InChiKey: JQRMTILWXFKYAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-methyl-1,2-dihydroquinoline 生成 7-methyl-1-tosyl-1,2-dihydroquinoline
  参考文献：
  名称：

  Rosenmund et al., Chemische Berichte, 1954, vol. 87, p. 1229,1233

  摘要：

  DOI：
• 作为产物：
  描述：

  7-甲基喹啉 在 四氢呋喃 、 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 7-methyl-1,2-dihydroquinoline
  参考文献：
  名称：

  Rosenmund et al., Chemische Berichte, 1954, vol. 87, p. 1229,1233

  摘要：

  DOI：

文献信息

• Enantioselective Synthesis of 4-Aminotetrahydroquinolines via 1,2-Reductive Dearomatization of Quinolines and Copper(I) Hydride-Catalyzed Asymmetric Hydroamination
  作者：Qing-Feng Xu-Xu、Xiao Zhang、Shu-Li You

  DOI：10.1021/acs.orglett.9b02034

  日期：2019.7.5

  1,2-reductive dearomatization of quinolines and copper(II) acetate monohydrate/(R,R)-Ph-BPE/P(p-tolyl)3-catalyzed enantioselective hydroamination sequence was developed, affording diverse 4-amino-1,2,3,4-tetrahydroquinolines with high levels of enantioselectivity in either a stepwise or one-pot fashion. Pleasingly, internal cis-cyclic alkenes, which are challenging substrates in copper hydride-catalyzed

  开发了喹啉和一水合乙酸铜（II）/（R，R）-Ph-BPE / P（对甲苯基）3-催化的对映选择性加氢胺化反应的1,2-还原脱芳香化反应，提供了多种4-氨基-1，具有高对映选择性的2,3,4-四氢喹啉，呈逐步或一锅方式。令人愉快的是，在氢化铜催化的对映选择性加氢胺化反应中具有挑战性的底物内部顺式环烯烃在温和条件下得到了有效转化。
• Enantioselective Synthesis of 4-Allyl Tetrahydroquinolines via Copper(I) Hydride-Catalyzed Hydroallylation of 1,2-Dihydroquinolines
  作者：Qing-Feng Xu-Xu、Xiao Zhang、Shu-Li You

  DOI：10.1021/acs.orglett.0c00113

  日期：2020.2.21

  CuCl/(R,R)-Ph-BPE-catalyzed asymmetric hydroallylation of 1,2-dihydroquinolines, prepared from readily available quinolines, was developed. The optically active tetrahydroquinolines (THQs) bearing an allylic functionality at position 4 were obtained in good yields and excellent enantioselectivity. The introduced allylic groups are amenable to diverse transformations, thus offering chances to rapidly

  开发了CuCl /（R，R）-Ph-BPE催化的1,2-二氢喹啉的不对称加氢水解反应，该反应由容易获得的喹啉制备。以良好的收率和优异的对映选择性获得了在4位具有烯丙基官能团的旋光四氢喹啉（THQ）。引入的盟友小组可以进行各种转换，从而为快速扩展THQ库提供了机会。
• Inhibitors of syk and JAK protein kinases
  申请人：Jia Zhaozhong

  公开号：US20100048567A1

  公开（公告）日：2010-02-25

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V的化合物及其互变异构体或药学上可接受的盐、酯和前药，其是syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，包含这种化合物的制药组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种疾病的方法，例如不良血栓和非何杰金淋巴瘤。
• INHIBITORS OF PROTEIN KINASES
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150094298A1

  公开（公告）日：2015-04-02

  The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-II的化合物及其药学上可接受的互变异构体、盐或立体异构体，它们是syk和/或JAK激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制syk和/或JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk和/或JAK激酶活性介导的多种疾病，例如不良血栓形成和非霍奇金淋巴瘤的方法。
• INHIBITORS OF SYK AND JAK PROTEIN KINASES
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20150297595A1

  公开（公告）日：2015-10-22

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V化合物及其互变异构体或药物可接受的盐、酯和前药，它们是Syk激酶抑制剂。本发明还涉及用于制备这种化合物的中间体，这种化合物的制备，含有这种化合物的制药组合物，抑制Syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由Syk激酶活性介导的多种疾病的方法，例如不良血栓形成和非霍奇金淋巴瘤。